0.00
0.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oxurion
Its shares trade on Euronext Brussels under the ticker OXUR.BR. It has been listed since 7 July 2006. In the fiscal year to 31 December 2025, it reported revenue of €555,000 and a net loss of €3.7m. At that date it held total assets of €3.8m and shareholders' equity of −€12.9m.
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Jul 2006
- Employees
- 77
- Website
- oxurion.com ↗
Leadership
Pay as last reported
- Mr. Charles De BollardiereNon-Executive Independent Chairman of the Board€15,000
- Mr. Pascal GhosonChief Executive Officer, Chief Financial Officer, Executive Director - Permanent Representative of MARS SARL, Member of the Executive Committee, since 2023€280,000
- Mr. Philippe BarbeauxChief Scientific Officer, Member of the Executive Committee
- Dr. Andy De DeeneChief Development Officer, Member of the Executive Committee, since 2020
- Mr. James HartmannNon-Executive Independent Director€10,000
- Ms. Nelly SouleymaneNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 16
- Social
- 95
- Governance
- 32
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- JETREA has FDA approval for treating symptomatic vitreomacular adhesion.
- The company partners with Alcon for commercialization outside the United States.
- Oxurion operates offices in the United States and Ireland.
Weaknesses
- The firm employs only 77 full-time staff members.
- JETREA was launched in January 2013, which is over a decade ago.
- The company is headquartered in Heverlee, Belgium, limiting local scale.
Opportunities
- Anti-PIGF TB-403 is being explored for ophthalmic indications.
- TB-403 is also under investigation for oncology treatments.
- JETREA is approved for vitreomacular traction in Europe.
Threats
- The company relies on Alcon for non-US commercialization.
- JETREA faces competition in the vitreo retinal disease market.
- Biotechnology development carries inherent clinical and regulatory risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.